

# Treating Diabetic Peripheral Neuropathic Pain

TAMMY J. LINDSAY, MD; BLAKE C. RODGERS, MD; VINCENT SAVATH, MD; and KEVIN HETTINGER, MD  
*Saint Louis University Family Medicine Residency Program, Belleville, Illinois*

Diabetic peripheral neuropathic pain affects the functionality, mood, and sleep patterns of approximately 10 to 20 percent of patients with diabetes mellitus. Treatment goals include restoring function and improving pain control. Patients can realistically expect a 30 to 50 percent reduction in discomfort with improved functionality. The main classes of agents used to treat diabetic peripheral neuropathic pain include tricyclic antidepressants, anticonvulsants, serotonin-norepinephrine reuptake inhibitors, opiates and opiate-like substances, and topical medications. Physicians should ask patients whether they have tried complementary and alternative medicine therapies for their pain. Only two medications are approved specifically for the treatment of diabetic peripheral neuropathic pain: pregabalin and duloxetine. However, evidence supports the use of other therapies, and unless there are contraindications, tricyclic antidepressants are the first-line treatment. Because patients often have multiple comorbidities, physicians must consider potential adverse effects and possible drug interactions before prescribing a medication. (*Am Fam Physician*. 2010;82(2):151-158. Copyright © 2010 American Academy of Family Physicians.)

► **Patient information:**  
A handout on diabetic peripheral neuropathic pain, written by the authors of this article, is provided on page 159.



This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME). See CME Quiz on page 127.

Peripheral neuropathy is a common complication of diabetes mellitus, occurring in 30 to 50 percent of patients with the disease.<sup>1</sup> It involves the loss of sensation in a symmetric stocking-and-glove distribution, starting in the toes and progressing proximally. Approximately 10 to 20 percent of patients with diabetes have diabetic peripheral neuropathic pain, which is a burning, tingling, or aching discomfort that worsens at night.<sup>1,2</sup> Patients with diabetic peripheral neuropathic pain may also experience allodynia and hyperalgesia. Diabetic peripheral neuropathic pain interferes with sleep quality, mood, and activity level. Initial management goals include controlling hyperglycemia, which may acutely worsen pain.<sup>3</sup> Although complete relief is ideal, pain reduction of only 30 to 50 percent can be expected in most patients taking maximal doses of medication.<sup>4,5</sup>

Available evidence on treating diabetic peripheral neuropathic pain is limited to small studies and few head-to-head trials. Although the American Society of Pain Educators has released consensus guidelines for treatment, they offer little guidance on choosing a first-tier agent.<sup>6,7</sup> *Figure 1* presents a treatment algorithm for diabetic peripheral neuropathic pain based on available evidence.<sup>4</sup> There are five main classes of medications and some alternative options used to treat diabetic peripheral neuropathic pain.


*Table 1* provides dosages, costs, and numbers needed to treat (NNT) of selected medications.<sup>5,8-29</sup> *Table 2* lists common adverse effects of the medications.<sup>5,8-11,14,18-20,30</sup>

Studies of medications used to treat diabetic peripheral neuropathic pain assess effectiveness primarily by measuring reduction in pain. Few studies have examined the effects of diabetic peripheral neuropathic pain on quality of life. However, one study used the Nottingham Health Profile, a validated quality-of-life questionnaire, to examine the quality of life in patients with diabetic peripheral neuropathic pain.<sup>31</sup> The study showed decreased quality of life in areas of sleep, energy, and exercise tolerance, as well as increased emotional reactivity, suggesting considerable benefits to treating diabetic peripheral neuropathic pain.

## Tricyclic Antidepressants

Tricyclic antidepressants (TCAs) are recommended as first-line therapy for diabetic peripheral neuropathic pain in appropriate patients, although their mechanism of action is uncertain. Physicians have been using TCAs, such as amitriptyline and nortriptyline (Pamelor), to treat neuropathic pain for years, without approved labeling from the U.S. Food and Drug Administration (FDA).<sup>8</sup> An updated Cochrane review of antidepressants for treating neuropathic pain revealed an overall effectiveness, with an NNT of 1.3

## Management of Diabetic Peripheral Neuropathic Pain



### Add at any time

Lidocaine 5% patch (Lidoderm; one to three patches per day, up to 12 hours per day)

Capsaicin cream (Zostrix; 0.075% topical four times per day; minimum four- to eight-week trial to achieve results)

Trial of acupuncture

\*—Other causes of neuropathy include malignancy, alcohol use, human immunodeficiency virus infection, isoniazid use, and chemotherapy.

†—TCAs should be avoided in patients older than 60 years and are relatively contraindicated in patients with glaucoma, urinary retention, benign prostatic hyperplasia, impaired liver function, thyroid disease, and cardiac conditions, including heart failure, arrhythmias, and orthostatic hypotension.

‡—Use of carbamazepine requires monitoring of blood urea nitrogen, creatinine, transaminase, and iron levels, as well as performing a complete blood count, reticulocyte count, liver function test, and urinalysis. A lipid panel and drug levels are recommended every six to 12 months.

§—Effects of tramadol do not become apparent until after one month of therapy.

for diabetic neuropathy based on five studies involving TCAs.<sup>8</sup>

Although TCAs are generally affordable and effective, they should be used with caution. One in five patients discontinues therapy because of adverse effects.<sup>8</sup> Potential drug interactions must be reviewed. Any cardiac history, including heart failure, arrhythmias, or recent myocardial infarction, is a contraindication for TCAs. Because of the anticholinergic effects of TCAs, physicians should be cautious when prescribing them for patients with narrow-angle glaucoma, benign prostatic hypertrophy, orthostasis, urinary retention, impaired liver function, or thyroid disease. QTc interval should be assessed in those with additional risk factors: syncope or presyncope, cardiovascular disease, electrolyte disturbance, and older age.<sup>8,32</sup> If QT prolongation is present, other medications should be used because of the risk of torsades de pointes. Care should be exercised in patients older than 60 years because of the increased likelihood of comorbidities.<sup>6-8,33</sup>

### Anticonvulsants

Anticonvulsants are divided into two categories: newer (e.g., gabapentin [Neurontin], pregabalin [Lyrica]) and traditional (e.g., carbamazepine [Tegretol], valproate [Depacon]). Evidence is lacking for the use of other newer anticonvulsants, such as topiramate (Topamax) and lamotrigine (Lamictal).<sup>34,35</sup>

Based on available evidence, gabapentin and pregabalin should be used as first-line treatment for diabetic peripheral neuropathic pain if there are contraindications or an inadequate response to TCAs.<sup>6</sup> Although their mechanism of action is not completely understood, pregabalin and gabapentin bind to the  $\alpha_2$ -delta subunit of the calcium-sensitive channels, modulating neurotransmitter release. Pregabalin is one of only two medications approved by the FDA for the treatment of diabetic peripheral neuropathic pain. In a 2008 meta-analysis of seven trials, pregabalin was used to treat diabetic peripheral neuropathic pain in 1,510 patients, and the results showed effectiveness with a dose-related response.<sup>10</sup> When compared with placebo, measurable pain relief was achieved with 150, 300, or 600 mg per day, divided into three doses. However, pain control occurred earlier with higher dosages (at day 4 with 600 mg versus day 13 with 150 mg).<sup>10</sup>

A 2005 Cochrane review evaluating the use of gabapentin in painful neuropathy calculated a combined NNT of 4.3 from five studies of diabetic peripheral neuropathic pain and two studies of postherpetic neuralgia and mixed neuralgia.<sup>11</sup> Because gabapentin is not protein-bound and is excreted unchanged in the urine,

**Figure 1.** Algorithm for treatment of diabetic peripheral neuropathic pain. (TCAs = tricyclic antidepressants.)

Information from reference 4.

**Table 1. Medications Used to Treat Diabetic Peripheral Neuropathic Pain**

Drug*	Dosage	Cost of generic (brand)†	Comments
Amitriptyline‡	10 to 150 mg at bedtime	\$12 (NA)§	NNT = 1.3, NNH = 28 (major adverse events)
Nortriptyline‡ (Pamelor)	25 to 150 mg at bedtime	\$13 (\$692)§	NNH = 6 (minor adverse events)§
Desipramine‡ (Norpramin)	25 to 150 mg at bedtime	\$23 (\$44)	
Pregabalin (Lyrica)	150 to 600 mg per day, divided into two or three doses 300 mg twice per day 100 mg three times per day 50 mg three times per day	NA (\$168)	NNT = 3.3, NNH = 3.7 <sup>9</sup> NNT = 4.0 <sup>10</sup>    NNT = 6.0 <sup>10</sup>    NNT = 19.1 <sup>10</sup>
Gabapentin (Neurontin)	300 to 1,200 mg three times per day	\$60 (\$182)	NNT = 4.3, NNH = 3.7 <sup>11</sup>
Carbamazepine (Tegretol)	200 to 600 mg twice per day	\$10 (\$86)§	NNT = 3.3, NNH = 1.9 <sup>9</sup>    NNT = 2.5, NNH = 3.7 <sup>12</sup>
Venlafaxine, extended release (Effexor XR)	150 to 225 mg per day	\$142 (\$150)	NNT = 3.1, NNH = 16.2 (major adverse effect) NNH = 9.6 (minor adverse effect) <sup>8</sup>
Duloxetine (Cymbalta)	60 to 120 mg per day	NA (\$154)	NNT = 5.1, <sup>5,13</sup> NNH = 15 <sup>5</sup>
Morphine	15 to 120 mg per day	\$17	Adverse effects and potential for addiction may limit use; decreased tolerated dose with similar effectiveness when used with gabapentin <sup>14,15</sup>
Oxycodone, controlled release (Oxycontin)	10 to 40 mg twice per day	\$61 (\$152)	NNT = 2.6 based on single small RCT <sup>16</sup> Another RCT showed benefit <sup>17</sup>    NNH = 8 <sup>16</sup> (adverse effects led to withdrawal from study)
Tramadol (Ultram)	200 to 400 mg per day	\$64 (\$246)	NNT = 3.8, NNH = 7.7 (adverse effects led to withdrawal from study) <sup>18</sup>
Capsaicin cream (Zostrix)	0.075% topical cream four times per day	NA (\$22 per 57-g tube)	NNT = 5.7 (adverse effects make blinded trials difficult) NNH = 2.5 (local adverse effect) NNH = 9.8 (adverse effects led to withdrawal from study) <sup>19</sup>
Lidocaine 5% patch (Lidoderm)	Up to three patches per day, each patch worn up to 12 hours; patches may be worn at the same time; a 12-hour drug-free interval is necessary	NA (\$217 for one patch per day)	NNT = 4.4, <sup>20,21</sup> NNH = 29 <sup>20</sup>
L-carnitine	1,000 mg three times per day	\$40	Review of two RCTs showed improved pain and nerve fiber regeneration <sup>22</sup>
Alpha-lipoic acid	600 mg per day	\$10	Two RCTs showed conflicting results; long-term studies with oral formulation are needed <sup>23</sup>
Acupuncture	Types variable	\$60 to 120 per treatment	Small RCT and pilot study have shown benefit; a Cochrane review is underway <sup>24-26</sup>
Frequency-modulated electromagnetic neural stimulation	30 minutes per day	Depends on cost of hardware	Two small studies showed benefits alone and in conjunction with amitriptyline <sup>27-29</sup>

NA = not available; NNH = number needed to harm; NNT = number needed to treat; RCT = randomized controlled trial.

\*—Listed in order of recommended use.

†—Estimated retail price of one month's treatment based on lowest dosage provided. Information obtained at <http://www.drugstore.com> (accessed April 23, 2010). Generic price listed first; brand price listed in parentheses.

‡—Adverse effects make blinding difficult; numerous adverse effects and contraindications.

§—In retail discount program; may be available at discounted prices (\$10 or less for one month's treatment) at one or more national retail chains.

||—NNT based on diabetic peripheral neuropathic pain specifically (others based on generalized neuropathic pain).

Information from references 5, and 8 through 29.

**Table 2. Common Adverse Effects from Treatment for Diabetic Peripheral Neuropathic Pain**

Drug	Adverse effect	Patients who experienced effect (%)	Drug	Adverse effect	Patients who experienced effect (%)
Amitriptyline* <sup>8,30</sup>	Constipation	14	Opiates <sup>14</sup>	Constipation	33
	Dizziness	28		Dizziness	21
	Dry mouth	90		Nausea	33
	Somnolence	66		Somnolence	29
				Vomiting	15
Capsaicin cream (Zostrix) <sup>19</sup>	Cough	8	Pregabalin (Lyrica) <sup>†9,10</sup>	Dizziness	7 to 28
	Skin irritation	54		Edema	6 to 16
Duloxetine (Cymbalta) <sup>5,19</sup>	Constipation	9		Somnolence	5 to 13
	Diarrhea	6	Weight gain	4 to 9	
	Fatigue	9	Tramadol (Ultram) <sup>18</sup>	Constipation	22
	Headache	10		Headache	17
	Nasopharyngitis	6		Nausea	23
	Nausea	22	Somnolence	12	
	Somnolence	8	Venlafaxine (Effexor) <sup>8</sup>	Anorexia	5
	Sweating	6		Dyspepsia	10
Gabapentin (Neurontin) <sup>11</sup>	Confusion	7		Flatulence	6
	Diarrhea	10		Impotence	5
	Dizziness	24		Insomnia	10
	Headache	10	Myalgia	5	
	Nausea	8	Nausea	10	
Lidocaine 5% patch (Lidoderm) <sup>20</sup>	Somnolence	20	Sinusitis	7	
	No adverse effects significantly different from placebo	—	Somnolence	15	
			Sweating	10	
			Vomiting	5	

\*—Amitriptyline chosen to represent tricyclic antidepressants.

†—Range of percentages is based on range of doses in study; adverse effects were dose-related.

Information from references 5, 8 through 11, 14, 18 through 20, and 30.

it has few drug interactions. However, the review concluded that although gabapentin is effective for neuropathic pain, physicians should consider the cost before prescribing. The Cochrane authors recommended further study comparing medication classes.<sup>11</sup>

Traditional anticonvulsants, such as carbamazepine, phenytoin (Dilantin), and valproate, have been used to treat neuropathy since the 1960s.<sup>36</sup> Carbamazepine is FDA-approved for neuropathic pain, but not specifically for diabetic peripheral neuropathic pain. One Cochrane review examined 12 studies including 404 participants with a variety of types of neuropathic pain. The review found an NNT of 2.5 to achieve moderate pain relief with carbamazepine.<sup>12</sup> Adverse effects included drowsiness, dizziness, constipation, nausea, and ataxia.<sup>12</sup>

Laboratory monitoring is important to consider when prescribing carbamazepine. Before beginning treatment,

the patient's blood urea nitrogen, creatinine, transaminase, and iron levels should be checked, and a complete blood count (including platelets), reticulocyte count, liver function test, and urinalysis should be performed. A lipid panel and measurement of drug levels are also recommended every six to 12 months.<sup>37,38</sup> Additionally, carbamazepine carries a boxed warning for serious dermatologic reactions, including toxic epidermal necrolysis and Stevens-Johnson syndrome.<sup>37</sup> Risk is increased 10-fold in conjunction with human leukocyte antigen-B\*1502, which occurs almost exclusively in Asians. Physicians should perform genetic testing before initiating carbamazepine in this population.<sup>12</sup>

Because of the need for laboratory monitoring and the risk of drug interactions, newer anticonvulsants are preferred over carbamazepine.<sup>12</sup> Valproate and phenytoin have not been investigated as extensively as

carbamazepine, but have many of the same drawbacks.<sup>4,6,39</sup> Phenytoin has the added complication of elevating glucose levels, making it less appealing for use in patients with diabetic peripheral neuropathic pain.<sup>9</sup>

### SNRIs and SSRIs

Studies suggest that diabetic peripheral neuropathic pain is related to an unbalanced release of norepinephrine and serotonin from neurons.<sup>5,13</sup> Serotonin-norepinephrine reuptake inhibitors (SNRIs), including venlafaxine (Effexor) and duloxetine (Cymbalta), are a promising category of antidepressants for treatment of diabetic peripheral neuropathic pain. They are better tolerated and have fewer drug interactions than TCAs. A 2004 trial showed that higher doses of venlafaxine led to greater improvements in pain scores, likely because venlafaxine has a more balanced noradrenergic-to-serotonergic effect at higher doses.<sup>40</sup> A 2007 Cochrane review examined three studies of venlafaxine for neuropathic pain, revealing an NNT of 3.1.<sup>8</sup> This result is similar to that of TCAs for general neuropathic pain (NNT = 3.6). However, further studies are needed to investigate the effectiveness of venlafaxine for diabetic peripheral neuropathic pain specifically.

Duloxetine is the second drug approved for the treatment of diabetic peripheral neuropathic pain. Duloxetine is relatively balanced in its affinity for noradrenergic and serotonergic reuptake inhibition.<sup>5,13</sup> A 2006 randomized controlled trial (RCT) revealed similar effectiveness with 60 mg once per day and twice per day (NNT = 5.1).<sup>13</sup> The modified intention-to-treat analysis did not follow patients who dropped out of the study, which may have created a bias toward treatment.

Selective serotonin reuptake inhibitors (SSRIs) have also been used to treat diabetic peripheral neuropathic pain; however, there is only limited evidence showing a beneficial role. Although they are better tolerated than TCAs, the 2006 consensus guidelines list citalopram (Celexa) and paroxetine (Paxil) as options in the “other” category, after first- and second-tier agents, based on limited evidence and small trials.<sup>6</sup> The Cochrane Collaboration suggests that more high-quality studies are needed.<sup>8</sup>

### Opiates and Opiate-Like Medications

Monotherapy with opiates should be reserved for patients who do not achieve pain relief goals with other therapies. A 2006 Cochrane review evaluated the use of opiates for general neuropathic pain.<sup>14</sup> Methadone, levorphanol, morphine, and controlled-release oxycodone (Oxycontin) were included in the review. Nine intermediate-term (28-day average) studies involving 460 participants demonstrated the superiority of opiates over placebo.

Although these studies consistently showed benefit, only a portion of patients taking opiates achieved a modest pain reduction of approximately 20 to 30 percent, and were not evaluated for longer than eight weeks.<sup>14</sup> Despite concerns about dependency and controversial evidence for the benefit of chronic opiate therapy for nonmalignant pain, consensus guidelines suggest a benefit in patients with diabetic peripheral neuropathic pain.<sup>41</sup> Caution should be used because chronic opiate use leads to tolerance and hyperalgesia.<sup>42,43</sup>

Tramadol (Ultram) is a synthetic, opiate-like medication. It acts centrally at the mu-opioid receptors and weakly inhibits the central neuronal reuptake of norepinephrine and serotonin. A 1998 RCT of 131 participants revealed that patients taking tramadol scored better in pain control, quality-of-life measures, and physical and social functioning.<sup>44</sup> Because it lowers the seizure threshold, tramadol should be avoided in patients with epilepsy or in those at risk of seizures.<sup>18</sup> Although there is lower potential for abuse in patients taking tramadol compared with opiates, tramadol should not be used in patients who are opiate-dependent or who have a tendency to abuse drugs.<sup>44</sup> In patients taking tramadol, the NNT to achieve 50 percent pain reduction is 3.8.<sup>18</sup>

### Topical Medications

Common topical treatments for diabetic peripheral neuropathic pain include capsaicin cream (Zostrix) and lidocaine 5% patches (Lidoderm). Capsaicin stimulates the C fibers to release, and subsequently deplete, substance P. Many patients using capsaicin experience a stinging sensation during the first week of treatment, which dissipates with continued use. In a 2004 meta-analysis involving six trials of 656 patients, capsaicin had an NNT of 6.4 and 5.7 for 50 percent pain reduction at four and eight weeks, respectively.<sup>19</sup>

Lidocaine 5% patches block neuronal sodium channels. There have been small effectiveness trials with this medication. An RCT in 2003 revealed an NNT of 4.4 for 50 percent pain reduction.<sup>20</sup> Adverse effects are primarily dermatologic, resolving on removal of the patch. The primary advantage to topical treatment is that it can be added to systemic treatment at any time.

### Complementary and Alternative Medicine

As with many chronic conditions that interfere with quality of life, patients with diabetic peripheral neuropathic pain may explore complementary and alternative medicine (CAM) options. CAM therapies are being applied to diabetic peripheral neuropathic pain, although the data are limited. Asking patients about CAM treatments

**Table 3. Drug Interactions in Treatment for Diabetic Peripheral Neuropathic Pain**

<i>Drug</i>	<i>Interaction</i>	<i>Drug</i>	<i>Interaction</i>
Carbamazepine (Tegretol)	May increase toxic effects of CNS depressants* May decrease effectiveness of CYP1A2 substrates†, CYP2B6 substrates‡, CYP2C9 substrates§, CYP3A4 substrates  , oral contraceptives, thyroid medications, and TCAs Effects can be decreased by CYP3A4 inducers¶ Toxic effects can be increased by CNS depressants* and SSRIs Absolutely contraindicated with MAOIs	Pregabalin (Lyrica) and gabapentin (Neurontin)	May increase toxic effects of CNS depressants* Toxic effects can be increased by CNS depressants*
Duloxetine (Cymbalta)	May increase toxic effects of CNS depressants*, SSRIs, and warfarin (Coumadin) May decrease effectiveness of TCAs Effects can be decreased by CYP1A2 inducers** Toxic effects can be increased by CNS depressants* and SSRIs Absolutely contraindicated with MAOIs	Tramadol (Ultram)	May increase toxic effects of CNS depressants* and SSRIs Toxic effects can be increased by CNS depressants*, SSRIs, and TCAs
Oxycodone, controlled release (Oxycontin) and morphine	May increase toxic effects of CNS depressants*, MAOIs, and SSRIs Effects can be decreased by CYP3A4 inducers¶ Toxic effects can be increased by CNS depressants*	TCAs	May increase toxic effects of CNS depressants*, QTC-prolonging agents††, SSRIs, St. John's wort, sulfonyleureas, tramadol, and warfarin Effects can be decreased by carbamazepine and St. John's wort Toxic effects can be increased by CNS depressants*, duloxetine, QTC-prolonging agents††, SSRIs, and St. John's wort Absolutely contraindicated with MAOIs
		Venlafaxine (Effexor)	May increase toxic effects of CNS depressants* and SSRIs Effects can be decreased by CYP3A4 inducers¶ Toxic effects can be increased by CNS depressants*, CYP2D6 inhibitors‡‡, CYP3A4 inhibitors§§, and SSRIs Absolutely contraindicated with MAOIs

CNS = central nervous system; CYP = cytochrome P450; MAOIs = monoamine oxidase inhibitors; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic antidepressants.

\*—Carbamazepine, gabapentin, opiates, pregabalin, tramadol, trazodone, and TCAs.

†—Duloxetine, estrogens, flutamide, mirtazapine (Remeron), propranolol, and ropinirole (Requip).

‡—Bupropion (Wellbutrin), cyclophosphamide, efavirenz (Sustiva), promethazine, and selegiline (Eldepryl).

§—Celecoxib (Celebrex), dapsone, fluoxetine (Prozac), fosphenytoin (Cerebyx), glimepiride (Amaryl), glipizide (Glucotrol), losartan (Cozaar), montelukast (Singulair), phenytoin (Dilantin), tamoxifen, trimethoprim/sulfamethoxazole (Bactrim, Septra), trimethoprim, and warfarin.

||—Alfuzosin (Uroxatral), amiodarone (Cordarone), atorvastatin (Lipitor), calcitriol (Rocaltrol), citalopram (Celexa), clonazepam (Klonopin), enalapril (Vasotec), estrogens, felodipine, ketoconazole, progesterones, and tetracycline.

¶—Carbamazepine, dexamethasone, efavirenz, fosphenytoin, phenytoin, and St. John's wort.

\*\*—Carbamazepine, phenobarbital, and rifampin.

††—Amiodarone, azithromycin (Zithromax), clarithromycin (Biaxin), fluoxetine, haloperidol (formerly Haldol), risperidone (Risperdal), and sotalol (Betapace).

‡‡—Amiodarone, celecoxib, cimetidine (Tagamet), clomipramine (Anafranil), desipramine (Norpramin), duloxetine, haloperidol, imipramine (Tofranil), isoniazid, ketoconazole, lidocaine (Xylocaine), methadone, pioglitazone (Actos), and sertraline (Zoloft).

§§—Amiodarone, cimetidine, clotrimazole (Lotrimin), cyclosporine (Sandimmune), desipramine, diltiazem (Cardizem), efavirenz, erythromycin, fluconazole (Diflucan), grapefruit juice, haloperidol, metronidazole (oral [Flagyl], gel [Metrogel]), sertraline, tetracycline, and verapamil.

Information from reference 46.

they are using can help physicians provide more complete care of the patient. CAM therapies with the most promise include L-carnitine and alpha-lipoic acid, which are available over the counter. Early studies have shown positive results, but more long-term data are needed.<sup>22,45</sup> Data involving acupuncture have been limited. However, a pilot study and small RCT have shown promise.<sup>24,25</sup> A Cochrane review is currently underway.<sup>26</sup>

### Combination Therapy and Drug Interactions

Because of the complicated drug interaction profiles of the medications used to treat diabetic peripheral neuropathic pain (Table 3<sup>46</sup>), it is advisable to exhaust

monotherapy options before considering combination therapy, with the exception of topical agents. Few studies have considered the role of combination therapy, although one study showed a decreased need for opiates when combined with gabapentin.<sup>15</sup> If combination therapy is necessary, physicians should consider the mechanism of action when choosing medications and consider consulting a pain management specialist.<sup>7</sup> It is important to avoid combining TCAs with SSRIs or SNRIs to avoid serotonin syndrome, a life-threatening condition with autonomic and neurologic symptoms.<sup>47</sup>

Before initiating therapy, physicians should thoroughly review medication lists for potential interactions

## SORT: KEY RECOMMENDATIONS FOR PRACTICE

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
First-line treatment of diabetic peripheral neuropathic pain includes tricyclic antidepressants (e.g., amitriptyline, nortriptyline [Pamelor]). If these agents are contraindicated, newer anticonvulsants (e.g., gabapentin [Neurontin], pregabalin [Lyrica]) should be considered.	B	6, 8-11
Serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine [Effexor], duloxetine [Cymbalta]) or opiates and opiate analogs (e.g., morphine, tramadol [Ultram]) may be used if first-line treatments are unsuccessful.	B	8, 13, 14, 18, 44
Topical treatments (e.g., capsaicin cream [Zostrix], lidocaine 5% patches [Lidoderm]) may be added to systemic treatments at any time.	B	19, 20

*A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort.xml>.*

in patients with comorbidities. Drugs that may interact with diabetic peripheral neuropathic pain therapies include statins, beta blockers, sulfonyleureas, levothyroxine, warfarin (Coumadin), and loop diuretics. Drug interactions stem primarily from hepatic metabolism through the cytochrome P450 system or because a drug is highly protein bound.<sup>48</sup>

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Air Force Medical Department or the U.S. Air Force at large.

This is one in a series of "Clinical Pharmacology" articles coordinated by Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency at Cambridge Health Alliance, Malden, Mass.

### The Authors

TAMMY J. LINDSAY, MD, FAAFP, is associate program director of the Saint Louis University Family Medicine Residency Program in Belleville, Ill., which is affiliated with Scott Air Force Base.

BLAKE C. RODGERS, MD, is an assistant clinical professor in the Saint Louis University Family Medicine Residency Program in Belleville.

VINCENT SAVATH, MD, is a third-year resident at the Saint Louis University Family Medicine Residency Program in Belleville.

KEVIN HETTINGER, MD, is a third-year resident at the Saint Louis University Family Medicine Residency Program in Belleville.

*Address correspondence to Tammy J. Lindsay, MD, FAAFP, Saint Louis University, 180 S. 3rd St., Ste. 400, Belleville, IL 62220 (e-mail: [tammy.lindsay@us.af.mil](mailto:tammy.lindsay@us.af.mil)). Reprints are not available from the authors.*

Author disclosure: Nothing to disclose.

### REFERENCES

- Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. *Pain Med.* 2007;8(suppl 2):S50-S62.
- Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. *Pain Med.* 2008;9(6):660-674.
- Lee JH, Cox DJ, Mook DG, McCarty RC. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. *Pain.* 1990;40(1):105-107.
- Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. *BMJ.* 2007;335(7610):87.
- Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. *BMC Neurol.* 2008;8:29.
- Argoff CE, Backonja MM, Belgrade MJ, et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. *J Fam Pract.* 2006;(suppl):1-19. [http://www.jfponline.com/uploadedFiles/Journal\\_Site\\_Files/Journal\\_of\\_Family\\_Practice/supplement\\_archive/Suppl\\_DPNP.pdf](http://www.jfponline.com/uploadedFiles/Journal_Site_Files/Journal_of_Family_Practice/supplement_archive/Suppl_DPNP.pdf). Accessed March 31, 2009.
- Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain [published correction appears in *Mayo Clin Proc.* 2006;81(6):854]. *Mayo Clin Proc.* 2006;81(4 suppl):S12-S25.
- Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database Syst Rev.* 2007;(4):CD005454.
- Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. *J Clin Endocrinol Metab.* 2005;90(8):4936-4945.
- Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. *Diabetes Care.* 2008;31(7):1448-1454.
- Wiffen PJ, McQuay HJ, Rees JE, Moore RA. Gabapentin for acute and chronic pain. *Cochrane Database Syst Rev.* 2005;(3):CD005452.
- Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. *Cochrane Database Syst Rev.* 2005;(3):CD005451.
- Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. *Neurology.* 2006;67(8):1411-1420.
- Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. *Cochrane Database Syst Rev.* 2006;(3):CD006146.
- Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. *N Engl J Med.* 2005;352(13):1324-1334.
- Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. *Pain.* 2003;105(1-2):71-78.
- Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. *Neurology.* 2003;60(6):927-934.
- Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. *Cochrane Database Syst Rev.* 2006;(3):CD003726.
- Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. *BMJ.* 2004;328(7446):991.
- Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. *Pain.* 2003;106(1-2):151-158.
- Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lode-wick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality

## Diabetic Neuropathic Pain

- of life of the 5% lidocaine patch in diabetic polyneuropathy. *Arch Neurol*. 2004;61(6):914-918.
22. Sima AA, Calvani M, Mehra M, Amato A; Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. *Diabetes Care*. 2005;28(1):89-94.
  23. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. *Diabetes Care*. 1999;22(8):1296-1301.
  24. Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. *Diabetes Care*. 2000;23(3):365-370.
  25. Ahn AC, Bennani T, Freeman R, Hamdy O, Kaptchuk TJ. Two styles of acupuncture for treating painful diabetic neuropathy—a pilot randomized control trial. *Acupunct Med*. 2007;25(1-2):11-17.
  26. Zhao T, Zhang R, Zhao H. Acupuncture for symptomatic treatment of diabetic peripheral neuropathy (Protocol). *Cochrane Database Syst Rev*. 2006;(4):CD006280.
  27. Kumar D, Alvaro MS, Julka IS, Marshall HJ. Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief. *Diabetes Care*. 1998;21(8):1322-1325.
  28. Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. *Diabetologia*. 2005;48(5):817-823.
  29. Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2010;74(2):173-176.
  30. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. *Neurology*. 1987;37(4):589-596.
  31. Benbow S, Wallymahmed M, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. *QJM*. 1998;91(11):733-737.
  32. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. *Drugs Aging*. 2009;26(12):997-1012.
  33. Berger A, Dukes E, Edelsberg J, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. *Clin J Pain*. 2007;23(3):251-258.
  34. Thienel U, Neto W, Schwabe SK, Vijapurkar U; Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. *Acta Neurol Scand*. 2004;110(4):221-231.
  35. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. *Cochrane Database Syst Rev*. 2007;(2):CD006044.
  36. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 10th ed. New York, NY: McGraw-Hill; 2001:533.
  37. Tegretol (carbamazepine) [package insert]. East Hanover, N.J.: Novartis Pharmaceuticals Corporation; 2008.
  38. Paton C, Procter AW. Carbamazepine monitoring. *Psychiatr Bull*. 1993;17(12):718-720.
  39. Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. *QJM*. 2004;97(1):33-38.
  40. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [published correction appears in *Pain*. 2005;113(1-2):248]. *Pain*. 2004;110(3):697-706.
  41. Chou R, Fanciullo GJ, Fine PG, et al.; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain*. 2009;10(2):113-130.
  42. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. *Med Clin North Am*. 2007;91(2):199-211.
  43. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. *Clin J Pain*. 2008;24(6):469-478.
  44. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology*. 1998;50(6):1842-1846.
  45. Ametov AS, Barinov A, Dyck PJ, et al.; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial [published correction appears in *Diabetes Care*. 2003;26(7):2227]. *Diabetes Care*. 2003;26(3):770-776.
  46. Lexi-Comp [online reference library]. Hudson, Ohio: American Pharmaceutical Association; 2009. Updated daily. <http://online.lexi.com> (subscription required). Accessed October 27, 2009.
  47. Boyer EW, Shannon M. The serotonin syndrome [published corrections appear in *N Engl J Med*. 2009;361(17):1714 and *N Engl J Med*. 2007;356(23):2437]. *N Engl J Med*. 2005;352(11):1112-1120.
  48. Gore M, Sadosky A, Leslie D, Sheehan AH. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the U.K. and Germany Medplus databases. *Pain Pract*. 2008;8(4):253-262.